Bruikman Caroline S, Stoekenbroek Robert M, Hovingh G Kees, Kastelein John P
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Can J Cardiol. 2017 Mar;33(3):350-357. doi: 10.1016/j.cjca.2016.09.010. Epub 2016 Oct 17.
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CVD), is caused by the multifactorial interaction of various conditions, and dyslipidemia is widely acknowledged as 1 of the crucial risk factors in this process. Statin drugs have been shown to decrease low-density lipoprotein cholesterol and CVD morbidity as well as mortality and are therefore pivotal in CVD prevention. Despite the use of statin drugs, CVD remains a leading cause of mortality worldwide, which suggests that additional lipid-lowering therapies are warranted. Several novel therapeutic agents, which are described in this review, are now well on their way in their respective development paths and might revolutionize anti-atherosclerotic drug therapy.
动脉粥样硬化是最终导致临床心血管疾病（CVD）的潜在过程，它由多种情况的多因素相互作用引起，而血脂异常被广泛认为是这一过程中的关键危险因素之一。他汀类药物已被证明可降低低密度脂蛋白胆固醇以及CVD的发病率和死亡率，因此在CVD预防中起着关键作用。尽管使用了他汀类药物，但CVD仍然是全球主要的死亡原因，这表明有必要采用额外的降脂疗法。本文综述中描述的几种新型治疗药物目前在各自的研发道路上进展顺利，可能会彻底改变抗动脉粥样硬化药物治疗。
